AGS67E, an antibody‒drug coupling agent against CD37, has shown partial efficacy and a favorable safety profile in clinical trials for the treatment of CTCL [39]. The gene discussed is CD37; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.